prnewswire.comOCT 91 min read$CI

The Cigna Group's Third Quarter 2026 Earnings Release Details

The Cigna Group (NYSE:CI) will release its Q3 2026 earnings on November 5, 2026, at 6:30 a.m. ET, followed by a conference call at 8:30 a.m. ET. The call will be available via webcast and replay. Financial details will be posted on the company's investor relations website.

Original reporting

prnewswire.com

Published Oct 9, 2026, 10:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 9, 2026, 10:03 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · prnewswire.com

Decision brief

The 30-second read

$CINeutralLow

Why it matters

The announcement of the earnings release date provides a timing cue for traders but contains no new financial data.

Market read

The article is a standard earnings release notice with limited immediate trading impact.

What to watch

Potential impact of recent regulatory changes on Cigna's Medicare Advantage business.

Relevance 4/10Novelty 3/10Timing: pre‑market on Nov 5 2026

Background

Cigna (NYSE:CI) is a global health services company that regularly reports quarterly earnings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CINeutralHigh confidence

Context

Cigna will release its Q3 2026 earnings on November 5, 2026.

Expected impact

likely neutral as market already priced in expectations

Evidence & confidence

No new guidance or numbers are provided, only the release schedule.

Market effects

Sector

Health insurance sector may see slight attention ahead of the earnings window.

Regional

U.S. markets may experience minor volatility around the release time.

Global

Limited to investors tracking U.S. health insurers.

Counterpoint

What could challenge this read

If the market has over‑priced the upcoming results, a surprise miss could trigger a sell‑off.

Key entities

company
The Cigna Group
Global health insurer and the subject of the earnings release.

Read at source ← All news

OCT 2

$CIHighAI 8/10

Bernstein raises Cigna stock price target on specialty pharmacy growth

Bernstein raised its price target for Cigna (NYSE:CI) to $387, citing growth in specialty pharmacy. Cigna set 2026-2030 targets, including 10-14% adjusted earnings growth. Q2 2026 earnings beat expectations, with $7.78 EPS and $71.7B revenue. Analysts have mixed outlooks, with UBS targeting $400 and Evercore ISI at $290.

investing.com2 min

OCT 1

$CIMedAI 8/10

Key facts: CI affirms 2026 targets; exits ACA; eyes specialty pharmacy

Cigna (CI) reaffirmed 2026 targets, including $280B revenue and $30.45 EPS. The company will exit the ACA marketplace, cut insurance growth targets, and focus on specialty pharmacy. Shares fell 2% intraday. CI also launched an AI program to reduce medical costs by $200M over three years.

tradingview.com1 min

SEP 30

$CIMed

Cigna sets aside $3B to boost performance (CI:NYSE)

Cigna (CI) announced a $3B multi-year initiative to enhance performance using AI and productivity tools. The company also outlined financial targets for 2026–2030 during its Investor Day.

seekingalpha.com1 min

SEP 30

$CIMed

The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities

Cigna Group (CI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities • Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned

SEC EDGAR 8-K2 min

SEP 24

$NVOMed

GLP-1 prices are falling but a big change could affect what you pay

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.

nbcdfw.com3 min

SEP 22

$UNHMed

U.S. to remove hundreds of thousands of Obamacare enrollees

The Trump administration plans to remove 750,000 ACA enrollees due to alleged fraud, saving $2.2B. Affected individuals include those unaware of enrollments, high earners, and those with employer-provided healthcare. Leading ACA marketplace operators traded lower on the news.

tradingview.com2 min